KaloBios Pharmaceuticals (KBIO) made its public debut on Thursday, January 31th. Shares of the biopharmaceutical company ended their first day unchanged at $8.00 per share. From that point in time, shares have gradually lost ground, closing at $7.20 per share on Friday.
The Public Offering
KaloBios Pharmaceutical is a biopharmaceutical company which is focused on the development of monoclonal antibody therapeutics. The company has developed a proprietary Humaneered antibody technology focused on respiratory diseases and cancer.
Read the entire article on Seekingalpha by clicking the following link
No comments:
Post a Comment